Comparison of no adjuvant treatment and radiotherapy in early-stage cervical carcinoma with intermediate risk factors

被引:17
作者
Akilli, Huseyin [1 ]
Tohma, Yusuf A. [2 ]
Bulut, Ayca N. [3 ]
Karakas, Latife Atasoy [2 ]
Haberal, Asuman N. [4 ]
Kuscu, Ulku E. [1 ]
Ayhan, Ali [1 ]
机构
[1] Baskent Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Sch Med, Ankara, Turkey
[2] Baskent Univ, Dept Obstet & Gynecol, Sch Med, Ankara, Turkey
[3] City Hosp, Dept Obstet & Gynecol, Kayseri, Turkey
[4] Baskent Univ, Dept Pathol, Sch Med, Ankara, Turkey
关键词
Adjuvant treatment; Disease-free survival; Early-stage cervical cancer; Intermediate risk factors; Local recurrence; Radiotherapy; RADICAL HYSTERECTOMY; RADIATION-THERAPY; CANCER-PATIENTS; IB; CHEMOTHERAPY; SURGERY;
D O I
10.1002/ijgo.13147
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the results of receiving no adjuvant treatment (NAT) or radiotherapy after radical hysterectomy in patients with International Federation of Gynecology and Obstetrics 2018 Stage IB1-IB3 cervical cancer with intermediate risk factors. Methods A retrospective cohort study was conducted at Baskent University School of Medicine's Department of Gynecology and Obstetrics in Ankara, Turkey between January 1, 2008, and December 31, 2016. In total, 134 women with at least two intermediate risk factors (positive LVSI, deep stromal invasion, and tumor size >= 4 cm) were included in the study. Patients were divided into two groups: NAT and radiotherapy. Results There were 66 patients in the NAT group and 68 in the radiotherapy group. The median follow-up time was 61.05 months. The 5-year overall survival (OS) rates were similar in both groups (84.1% vs 82.9%, respectively; P=0.57), while the 5-year disease-free survival (DFS) rates were 80.2% and 78.2% in the NAT and radiotherapy groups, respectively (P=0.25). Most importantly, both groups had similar local recurrence rates: 8 (12.1%) in the NAT group and 9 (13.2%) in the radiotherapy group (P=0.82). Multivariant analyses showed that the only independent risk factor for recurrence was tumor size >= 4 cm with a hazard ratio of 2.4 (95% confidence interval 1.12-5.24; P=0.02). Conclusion Adjuvant treatment improved neither DFS nor local recurrence rates.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 19 条
[1]  
AYHAN A, 1991, EUR J SURG ONCOL, V17, P492
[2]  
BILEK K, 1982, ARCH GESCHWULSTFORSC, V52, P223
[3]   Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature [J].
Cibula, David ;
Abu-Rustum, Nadeem R. ;
Fischerova, Daniela ;
Pather, Selvan ;
Lavigne, Katie ;
Slama, Jiri ;
Alektiar, Kaled ;
Ming-Yin, Lin ;
Kocian, Roman ;
Germanova, Anna ;
Fruhauf, Filip ;
Dostalek, Lukas ;
Dusek, Ladislav ;
Narayan, Kailash .
GYNECOLOGIC ONCOLOGY, 2018, 151 (03) :438-443
[4]   The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer [J].
Cibula, David ;
Poetter, Richard ;
Planchamp, Francois ;
Avall-Lundqvist, Elisabeth ;
Fischerova, Daniela ;
Haie-Meder, Christine ;
Koehler, Christhardt ;
Landoni, Fabio ;
Lax, Sigurd ;
Lindegaard, Jacob Christian ;
Mahantshetty, Umesh ;
Mathevet, Patrice ;
McCluggage, W. Glenn ;
McCormack, Mary ;
Naik, Raj ;
Nout, Remi ;
Pignata, Sandro ;
Ponce, Jordi ;
Querleu, Denis ;
Raspagliesi, Francesco ;
Rodolakis, Alexandros ;
Tamussino, Karl ;
Wimberger, Pauline ;
Raspollini, Maria Rosaria .
VIRCHOWS ARCHIV, 2018, 472 (06) :919-936
[5]   Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan [J].
Ikeda, Yuji ;
Furusawa, Akiko ;
Kitagawa, Ryo ;
Tokinaga, Aya ;
Ito, Fuminori ;
Ukita, Masayo ;
Nomura, Hidetaka ;
Yamagami, Wataru ;
Tanabe, Hiroshi ;
Mikami, Mikio ;
Takeshima, Nobuhiro ;
Yaegashi, Nobuo .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (03)
[6]   Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors [J].
Kim, K. ;
Kang, S. B. ;
Chung, H. H. ;
Kim, J. W. ;
Park, N. H. ;
Song, Y. S. .
EJSO, 2009, 35 (02) :192-196
[7]   Cervical Cancer, Version 3.2019 [J].
Koh, Wui-Jin ;
Abu-Rustum, Nadeem R. ;
Bean, Sarah ;
Bradley, Kristin ;
Campos, Susana M. ;
Cho, Kathleen R. ;
Chon, Hye Sook ;
Chu, Christina ;
Clark, Rachel ;
Cohn, David ;
Crispens, Marta Ann ;
Damast, Shari ;
Dorigo, Oliver ;
Eifel, Patricia J. ;
Fisher, Christine M. ;
Frederick, Peter ;
Gaffney, David K. ;
Han, Ernest ;
Huh, Warner K. ;
Lurain, John R., III ;
Mariani, Andrea ;
Mutch, David ;
Nagel, Christa ;
Nekhlyudov, Larissa ;
Fader, Amanda Nickles ;
Remmenga, Steven W. ;
Reynolds, R. Kevin ;
Tillmanns, Todd ;
Ueda, Stefanie ;
Wyse, Emily ;
Yashar, Catheryn M. ;
McMillian, Nicole R. ;
Scavone, Jillian L. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (01) :64-84
[8]   Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Marth, C. ;
Landoni, F. ;
Mahner, S. ;
McCormack, M. ;
Gonzalez-Martin, A. ;
Colombo, N. .
ANNALS OF ONCOLOGY, 2017, 28 :72-83
[9]   Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer [J].
Matsuo, Koji ;
Shimada, Muneaki ;
Yokota, Harushige ;
Satoh, Toyomi ;
Katabuchi, Hidetaka ;
Kodama, Shoji ;
Sasaki, Hiroshi ;
Matsumura, Noriomi ;
Mikami, Mikio ;
Sugiyama, Toru .
ONCOTARGET, 2017, 8 (63) :106866-106875
[10]   Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study) [J].
Nakamura, Kazuto ;
Kitahara, Yoshikazu ;
Satoh, Toyomi ;
Takei, Yuji ;
Takano, Masashi ;
Nagao, Shoji ;
Sekiguchi, Isao ;
Suzuki, Mitsuaki .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14